Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Drug-resistant bacteria over one million people worldwide each year. Bacteria develop resistance mechanisms via repeated exposure to antibiotics. Antibiotic overprescription, where antibiotics are used inappropriately, has significantly during the COVID-19 pandemic and contributed to the rise in bacterial antibiotic resistance cases.
β-lactam antibiotics, such as penicillin, interfere with the synthesis of peptidoglycans, key molecules that maintain the structural integrity of bacterial cells. Without peptidoglycans, bacteria are prone to cell lysis.
Bacteria can acquire resistance to these drugs by hydrolyzing β-lactam; thus, rendering it inactive, using the enzyme β-lactamases. There are two kinds of bacterial β-lactamases: serine- and metallo-β-lactamases, or MβLs, and no inhibitors currently exist for the latter. Therefore, scientists like set out to study MβLs and how they acquire drug resistance.
Vila was this month’s speaker on ASBMB Breakthroughs, a webinar series highlighting research from ¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ« journals. He is a professor of biophysics at the University of Rosario, Argentina, and an associate editor of the Journal of Biological Chemistry, or JBC. During his talk, sponsored by JBC, Vila shared his decades-long on MβLs.
In the early 2000s, Vila’s team MβLs’ dependence on zinc. Without this crucial metal, these enzymes cannot bind to their substrates.
“The loss of zinc reveals an Achilles’ heel of MβLs,” Vila said.
Vila and his colleagues showed that this dependence is crucial , or the gel-like space between the inner and outer bacterial cell membranes, where MβLs cleave β-lactam antibiotics. Vila emphasized the importance of studying MβL activity in the periplasm, rather than in test tubes in the lab, to preserve their native context.
“In the past decade, our lab’s main driving force has been to fill the gap between in vitro protein studies and the resistance phenotypes we’re seeing in the clinic,” he said.
A previous study that immune system activation in mice caused the cellular concentration of metal ions, such as zinc, to plummet. Vila’s team that such a lack of zinc in the periplasm destabilized MβLs, althought not all MβLs were affected equally.
They discovered that the membrane-bound New Delhi MβL 1, or NDM-1, is much more stable than the soluble Verona integron-encoded MβL 2, or VIM-2, in a zinc-depleted periplasm. In addition, NDM-1 which was genetically engineered to be soluble, lost this stability. Based on these results, they concluded that membrane anchoring stabilizes MβLs in the absence of zinc.
In a later , Vila’s team performed nuclear magnetic resonance, or NMR, spectroscopy in live cells to provide a structural explanation for this phenomenon in the bacterial periplasm.
“It’s really important to understand what’s going on in live bacterial cells at the atomic level, and NMR is the only technique that will allow that,” Vila said.
Vila and his colleagues showed that the C-terminal region of zinc-deficient, or “apo,” NDM-1 is disordered and flexible, but its zinc-bound, or “holo,” counterpart, is not. This instability targets apo NDM-1 for degradation by bacterial serine proteases Prc and DegP.
In the same study, Vila’s group elucidated on a possible explanation for how antibiotic resistance evolved in NDM-6, an NDM-1 variant as a Tier-1 mutant for having high tolerance to zinc deprivation. The team showed that an alanine to valine mutation on residue 233 at the C-terminus of NDM-1 allowed its apo form to assume the ordered and inflexible configuration of its holo form; thus, escaping degradation by Prc and DegP. This mechanism can confer resistance by providing MβLs a much-needed stability when zinc is scarce, like at the host–pathogen interface, where bacteria are challenged by the host immune system.
“This ability to increase stability and escape degradation by proteases is completely new paradigm in the evolution of metallo-β-lactamases,” Vila said. “We still need to understand this process better, but I think that modulating MβL stability rather than inhibiting it is a good idea that is worth exploring.”
In case you missed it, you can watch Vila’s full Breakthroughs webinar here.
Up next
Biosynthesis and regulation of plant phenolic compounds
May 14, 2025 12:15–1 p.m. Eastern
Erich Grotewold of Michigan State University will present his research on plant gene regulatory networks.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Bacteriophage protein could make queso fresco safer
Researchers characterized the structure and function of PlyP100, a bacteriophage protein that shows promise as a food-safe antimicrobial for preventing Listeria monocytogenes growth in fresh cheeses.

Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.

Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.

Mapping fentanyl’s cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl’s effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.

Designing life’s building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.

Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.